Teplizumab Side Effects

Medically reviewed by Drugs.com. Last updated on Jun 19, 2023.

Applies to teplizumab: intravenous solution.

Serious side effects of Teplizumab

Along with its needed effects, teplizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking teplizumab:

More common

• Black, tarry stools
• bleeding gums
• blood in the urine or stools
• chest pain or tightness
• cough or hoarseness
• dizziness
• fever or chills
• headache
• itching, pain, redness, swelling, tenderness, or warmth on the skin
• loss of appetite
• lower back or side pain
• muscle aches or pain
• nausea
• painful or difficult urination
• pale skin
• pinpoint red spots on the skin
• rash
• red, tender, or oozing skin at the incision
• sneezing
• sore throat
• sores, ulcers, or white spots on the lips or in the mouth
• stomach pain
• stuffy or runny nose
• swollen glands
• trouble breathing
• unusual bleeding or bruising
• unusual tiredness or weakness

Less common

• Diarrhea
• difficulty swallowing
• faintness
• fast heartbeat
• general feeling of discomfort or illness
• joint pain or swelling
• muscle pain
• puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
• vomiting

Rare

• Large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs

For Healthcare Professionals

Applies to teplizumab: intravenous solution.

Dermatologic

Very common (10% or more): Rash (48%)

Common (1% to 10%): Urticaria

Uncommon (0.1% to 1%): Angioedema^[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, nausea^[Ref]

Hematologic

Very common (10% or more): Anemia (27%), leukopenia (21%), lymphopenia (74%), thrombocytopenia (13%)

Common (1% to 10%): Neutropenia^[Ref]

Hepatic

Common (1% to 10%): Increased alanine aminotransferase^[Ref]

Hypersensitivity

Common (1% to 10%): Cytokine Release Syndrome (CRS)^[Ref]

Immunologic

Common (1% to 10%): Serum sickness^[Ref]

Metabolic

Very common (10% or more): Liver transaminase elevations (56%)^[Ref]

In patients treated with this drug who experienced CRS, 56% of them reported increased liver transaminase levels: 64% were up to 2.5 times upper limit of normal (ULN), 32% were more than 2.5 to 5 times ULN, and 4.5% were 5-10 times ULN.^[Ref]

Other

Very common (10% or more): Decreased bicarbonate (15%), decreased blood calcium (19%)

Common (1% to 10%): Serious infection

Uncommon (0.1% to 1%): Peripheral and generalized edema^[Ref]

Respiratory

Common (1% to 10%): Nasopharyngitis^[Ref]

Nervous system

Very common (10% or more): Headache (11%)^[Ref]

Frequently asked questions

• What is Tzeild?
• How does Tzield work?
• How effective is Tzield?
• How is Tzield administered?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer